XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events
6 Months Ended
Jun. 30, 2020
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsIn July 2020, the Company and Oragenics, a related party, mutually agreed to terminate the ECC for the treatment of oral mucositis effective immediately. Accordingly, the Company will recognize the remaining balance of deferred revenue associated with the ECC totaling $2,823 as collaboration and licensing revenue during the third quarter of 2020.